Jupiter Topco LLC Makes New $52.60 Million Investment in BioAge Labs, Inc. $BIOA

Jupiter Topco LLC acquired a new stake in shares of BioAge Labs, Inc. (NASDAQ:BIOA) during the 2nd quarter, HoldingsChannel.com reports. The firm acquired 2,144,633 shares of the company’s stock, valued at approximately $52,597,000.

Several other hedge funds have also recently modified their holdings of the stock. Legal & General Group Plc bought a new position in shares of BioAge Labs during the second quarter worth $84,000. The Manufacturers Life Insurance Company purchased a new position in BioAge Labs during the second quarter valued at $234,000. Bank of Nova Scotia bought a new stake in BioAge Labs in the 2nd quarter valued at $490,000. BlackRock Inc. bought a new stake in BioAge Labs in the 2nd quarter valued at $69,831,000. Finally, Deutsche Bank AG purchased a new stake in BioAge Labs in the 2nd quarter worth $841,000.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on BIOA. Roth Capital restated a “buy” rating and set a $25.00 price objective on shares of BioAge Labs in a research report on Friday, July 31st. BTIG Research reissued a “buy” rating and set a $40.00 price target on shares of BioAge Labs in a research note on Monday, August 3rd. Needham & Company LLC cut their price target on BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a report on Friday, July 31st. Jefferies Financial Group set a $21.00 price target on BioAge Labs in a report on Friday, July 31st. Finally, Wall Street Zen cut BioAge Labs from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, BioAge Labs presently has an average rating of “Moderate Buy” and an average price target of $36.57.

BioAge Labs Trading Up 2.4%

BIOA opened at $10.08 on Friday. The stock has a 50-day moving average of $18.03 and a 200 day moving average of $18.25. BioAge Labs, Inc. has a 12 month low of $4.55 and a 12 month high of $25.95. The firm has a market cap of $462.67 million, a P/E ratio of -4.24 and a beta of 0.93.

BioAge Labs (NASDAQ:BIOA) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.07. The business had revenue of $2.45 million for the quarter. BioAge Labs had a negative return on equity of 28.99% and a negative net margin of 912.26%. On average, research analysts forecast that BioAge Labs, Inc. will post -2.45 earnings per share for the current fiscal year.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.